Redcare Pharmacy rating upgrades and target price revisions

Deutsche Bank Research raised its target price for Redcare Pharmacy to €102 from €99 and kept a “Buy” rating, citing higher full‑year guidance and a 12% increase in the 2026 adjusted EBITDA forecast. UBS analyst Olivier Calvet lifted the target price to €60 from €55 while maintaining a “Neutral” rating, noting that the new target remains below the current trading price and reflects operational improvements and growth prospects in the European online pharmacy market.

In related analyst updates, Jefferies left its rating on French infrastructure group Vinci unchanged at “Buy” with a €145 target, pointing to mixed traffic trends across regions. Barclays kept its “Underweight” stance on German automaker BMW with a €82.50 target, warning of a significant margin warning. Jefferies also maintained a “Hold” rating on luxury conglomerate LVMH with a €510 target, highlighting product availability as a gauge of consumer spending on luxury goods.